Status:
TERMINATED
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
Lead Sponsor:
Novartis
Conditions:
Macular Degeneration
Choroidal Neovascularization
Eligibility:
All Genders
50+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response obs...
Eligibility Criteria
Inclusion
- Subjects of either gender age 50 years or older
- Subfoveal choriodal neovascularization (CNV) due to age-related macular degeneration (AMD)
Exclusion
- Choriodal neovascularization due to causes other than AMD
- Prior treatment for neovascular AMD in the study eye
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00433017
Start Date
May 1 2007
End Date
July 1 2009
Last Update
April 21 2011
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative site
Vienna, Austria
2
Novartis Investigative site
Antwerp, Belgium
3
Novartis Investigative site
Aalborg, Denmark
4
Novartis Investigative site
Créteil, France